LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc. (LUCD) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (D-). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (2.9) | B+ (3.6) | D (1.5) | D- (1.1) | C+ (2.6) | C (2.3) |
| 2026-11-06 | B- (2.9) | B+ (3.6) | D (1.4) | D- (1.1) | C+ (2.7) | C (2.4) |
| 2026-10-30 | B- (2.9) | B+ (3.6) | D (1.5) | D (1.3) | C+ (2.7) | C (2.4) |
| 2026-10-23 | B- (3.0) | B+ (3.6) | D (1.4) | D (1.3) | C+ (2.6) | C (2.4) |
| 2026-10-16 | B- (2.9) | B+ (3.6) | D (1.4) | D (1.4) | C+ (2.6) | C (2.4) |